MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy
Z Hu, Q Zhang, Z He, X Jia, W Zhang… - Frontiers in …, 2024 - frontiersin.org
Immune checkpoint blockades (ICBs) have revolutionized cancer therapy through
unleashing anti-tumor adaptive immunity. Despite that, they are usually effective only in a …
unleashing anti-tumor adaptive immunity. Despite that, they are usually effective only in a …
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
JM Konen, H Wu, DL Gibbons - Trends in Pharmacological Sciences, 2024 - cell.com
Immune checkpoint blockade (ICB) therapy works by inhibiting suppressive checkpoints that
become upregulated after T cell activation, like PD-1/PD-L1 and CTLA-4. While the initial …
become upregulated after T cell activation, like PD-1/PD-L1 and CTLA-4. While the initial …
Advances and prospects of biomarkers for immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) activate anti-cancer immunity by blocking T cell
checkpoint molecules such as programmed death 1 (PD-1) and cytotoxic T lymphocyte …
checkpoint molecules such as programmed death 1 (PD-1) and cytotoxic T lymphocyte …
Immune checkpoint inhibitors: breakthroughs in cancer treatment
X Kong, J Zhang, S Chen, X Wang, Q Xi… - Cancer Biology & …, 2024 - cancerbiomed.org
Over the past two decades, immunotherapies have increasingly been considered as first-
line treatments for most cancers. One such treatment is immune checkpoint blockade (ICB) …
line treatments for most cancers. One such treatment is immune checkpoint blockade (ICB) …
Mechanism of TIM-3 Inhibition in Th1 Cells
Y Cai - 2024 - dash.harvard.edu
TIM-3 is a co-inhibitory receptor that regulates Interferon (IFN)-g-secreting CD4+ T helper 1
(Th1) cells and marks CD8+ T cells that are terminally exhausted. Considering that anti-TIM …
(Th1) cells and marks CD8+ T cells that are terminally exhausted. Considering that anti-TIM …